Wearable data company VivoSense raises $25 million and other digital health funding

Launching portable data analytics VivoSense scored $25 million in a Series A funding round co-led by Perceptive Xontogeny Ventures (PXV) Fund and Debiopharm Innovation Fund.

The Newport Beach, California-based company has developed wearable sensors that can be used in clinical trials to help monitor digital biomarkers. In addition to the sensors, the company has software called VivoSense, which helps interpret sensor data for research and patient care.

“This strategic investment from the Debiopharm Innovation Fund and the Perceptive Xontogeny Venture (PXV) Fund will enable VivoSense to accelerate the development of real-world digital clinical measurements from wearable and remote monitoring technologies,” said Dudley Tabakin, CEO of VivoSense in a “Measures trusted and valued by all stakeholders are the foundation on which all other innovation in digital health should be built. VivoSense is working to realize the potential of new measures and technologies in regulatory and medical decision-making to leverage the large-scale real-world data, bringing life-saving treatments to the patients who need them most.”

AI-assisted diagnosis of neurological disorders Altoida has taken in an additional $14 million in a Series A extension round led by M Ventures and Whitecap Venture Partners. This new cash infusion completes their total Series A raise of $20.3 million.

The brain health company uses AI, machine learning and augmented reality to collect cognitive biomarkers for the detection of neurological diseases. The data collection on the platform can be used to drive research and care for individuals with cognitive impairment.

The Washington-based startup plans to use the new money to boost its research and grow its product development. The company also plans to commercialize its product in the US and global markets.

“Altoida’s platform is the first to use augmented reality as a framework to simulate activities of daily living and to use AI to develop scientifically validated diagnostics of neurological disorders,” Altoida CEO Travis Bond said in a statement. “We are pleased that new investors have joined Altoida and that our existing investors are continuing their support. Having investors from both the biotech and technology industries with complementary insight, networking and commitment to innovation in neurology will help us in enable us to bring our products to patients and suppliers… and researchers sooner.”

Health Technology Company Zephyr AI announced a $18.5 million seed funding round. Lerner Group Investments llC and M-Cor Holdings led the funding round with participation from Allen Y. Chao, AME Cloud Ventures, BoxGroup, MedStar Health, Roger W. Ferguson, Steve Oristaglio, Verily and other strategic investors.

The company uses artificial intelligence and big data to drive drug discovery research and precision medicine efforts.

“This significant capital increase will help us expand our reach, including assembling complementary healthcare data sets, refining advanced machine learning models, and gaining actionable insights for better outcomes in patient care and drug discovery,” said David L. Morgan, CEO of Zephyr AI. in a statement.